- Reaction score
- 3,655
From what I've searched nobody knows about this and it slipped right past everyone in the hair loss community.
https://pdfs.semanticscholar.org/0abb/b2070ba52d932bf6bcc83f10d0e6f7975a63.pdf
Novan Therapeutics, a clinical-stage drug-development company, has developed drug candidate SB204, which releases nitric oxide when applied topically to the skin. Based on results from animal studies, locally available nitric oxide may inhibit skin steroidogenesis resulting in reduced levels of androgens like testosterone and 5α-dihydrotestosterone(5α-DHT). Androgens in skin are thought to stimulate oil production that drives the development of acne as well aspromote hair loss in men. By reducing androgen levels locally in skin, topical nitric oxide maylead to first-in-class local antiandrogen therapiesused to treat these disease processes.
SB204 significantly inhibited the growth of androgen-dependent hamster flank glands.Inhibition occurred faster at higher doses and was first evident at 14 days at the highest dose. After 28 days of dosing, all doses significantly inhibited flank gland growth compared to the gelvehicle control group (Figure 3).
Nonclinical studies performed to date have not shown any safety concerns or appreciable systemic exposure when applied topically to rodents and minipigs for as long as 28-days in repeat-dose studies. These results indicate that nitric oxide therapies applied topically may induce only local –and not systemic –effects on steroidogenesis and lipidbiosynthesis, suggesting SB204 has the potential to be a first-in-class local antiandrogen.
http://novan.com/pipeline/
It reached Phase 3 for acne just like Winlevi, but so far is only a "potential" application in Alopecia.